AbVision Inc.

AbVision Inc. (AVI), previously the Drug Discovery Group of BioVision Inc., is a privately held biopharmaceutical company headquartered in the San Francisco Bay Area. AVI’s most advanced drug discovery efforts aim to develop pipelines of cancer and infectious disease therapeutics that harness the natural power of the immune system to bring first-in-class and best-in-class drugs to the world. AVI asks the question: How can we utilize AVI’s antibody discoveries to facilitate the success in therapies? Frequently, the obstacles lie in the lack of enough sufficient antibody diversity for lead selection. AVI is ready with solutions that are based on our revolutionary approach to creating a diverse array of antibodies. With AVI’s proprietary antibody discovery platform, we are one of leading biopharmaceutical companies to have generated therapeutic and diagnostic antibodies from variety of conventional animals. AVI also pioneered the use of high-throughput reporter cell systems for functional screening of drug candidates. Furthermore, our computer surfacing technology for antibody can work not only in antibody humanization but also in antibody sequence optimization that greatly enhances solubility and stability for excellent manufacturing of drug candidates. AVI’s deep expertise in antibody discovery, protein expression and robust drug screening platforms allow us to identify exceptionally selective, high-affinity antibodies, which can be applied as mono-agents or chimeric antigen receptors in therapies. Our breakthroughs have led to several therapeutic candidates currently in preclinical trials.